Calliditas Therapeutics AB earnings
Annual earnings per share (SEK per share, as reported)
| Fiscal year | Period end | Diluted EPS | Basic EPS | Filed |
|---|---|---|---|---|
| 2023 | 2023-12-31 | SEK -8.69 | SEK -8.69 | 2026-06-19T06:18:49Z |
| 2022 | 2022-12-31 | SEK -7.78 | SEK -7.78 | 2026-06-19T06:18:49Z |
| 2021 | 2021-12-31 | SEK -9.84 | SEK -9.84 | 2026-06-19T06:18:49Z |
Revenue & profit (SEK)
| Concept | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | — | — | — |
| Profit for the year | -SEK 466.2M | -SEK 412.3M | -SEK 509.5M |
Methodology
Earnings per share comes from ifrs-full:DilutedEarningsLossPerShare /
ifrs-full:BasicEarningsLossPerShare; revenue from
ifrs-full:Revenue and profit from ifrs-full:ProfitLoss,
as tagged in Calliditas Therapeutics AB's ESEF annual reports (source:
filings.xbrl.org).
Figures are in SEK, as reported. Not investment advice.